FIELD: medicine; oncology.
SUBSTANCE: present group of inventions concerns treating tumors expressing SST-R5. That is ensured by administering an effective amount of the pharmaceutical composition containing the veldoreotid or its pharmaceutically acceptable salt encapsulated in the polymer microsphere, and an excipient selected from hydroxypropyl-β-cyclodextrin (HPBCD) or dextrose.
EFFECT: introduction of such composition provides effective treatment with reduced side effects due to higher solubility and bioavailability of the drug.
28 cl, 26 tbl, 7 ex, 29 dwg
Authors
Dates
2020-11-18—Published
2017-02-16—Filed